Acquisition Synergy Slayback's sale to a larger specialty pharma creates cross selling opportunities for complex injectables and private-label products within a broader portfolio; BD should explore integration opportunities with Azurity or other strategic buyers to expand distribution and development services.

Exclusive Licensing The track record of exclusive distribution deals and private-label licensing demonstrates a capability to negotiate exclusive arrangements; use this to target hospitals, distributors, and private label opportunities in niche therapeutic areas.

Complex Injectables Edge Specialization in complex injectables and other non solid oral products, plus a network of contract R&D and manufacturing partners, positions Slayback to win CDMO style collaborations and to supply hard-to-manufacture generics to pharma companies seeking differentiated offerings.

Hospital Market Access Past partnerships with healthcare players and a focus on critical care products suggest strong routes to hospital systems, pharmacies, and GPOs; leverage existing relationships and case studies to pitch reliable supply of high complexity generics.

Financial Flexibility Moderate revenue with meaningful funding and lean operations indicate readiness for milestone-based deals, co-development financing, or equity partnerships to accelerate scale and expand manufacturing capacity.